Vectors Post Market: A Study to Assess Pain Relief Using Spinal Cord Stimulation
Vectors Post Market: A Study to Assess Pain Relief Using Spinal Cord Stimulation (SCS) With High Dose (HD) Stimulation Parameters
調査の概要
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
California
-
La Mesa、California、アメリカ、91942-8901
- Pain Consultants of San Diego
-
Orange、California、アメリカ、92868
- Restore Orthopedics and Spine Center
-
-
Delaware
-
Wilmington、Delaware、アメリカ、19803
- Center for Interventional Pain and Spine
-
-
Georgia
-
Stockbridge、Georgia、アメリカ、30281-5023
- Pain Care
-
-
Maryland
-
Oxon Hill、Maryland、アメリカ、20745
- National Spine and Pain
-
-
Michigan
-
Wyoming、Michigan、アメリカ、49519
- Michigan Pain Consultants
-
-
Nevada
-
Henderson、Nevada、アメリカ、89052
- Comprehensive and Interventional Pain Management
-
-
New Jersey
-
Voorhees、New Jersey、アメリカ、08043-3512
- The Pain Management Center
-
-
New York
-
Rochester、New York、アメリカ、14618
- University of Rochester Neurosurgery Partners Pain Management
-
-
North Carolina
-
Huntersville、North Carolina、アメリカ、28078
- Carolinas Pain Center
-
-
Ohio
-
Columbus、Ohio、アメリカ、43210
- The Ohio State University Wexner Medical Center
-
-
Pennsylvania
-
Allentown、Pennsylvania、アメリカ、18103
- Lehigh Valley Healthcare Network
-
Bethlehem、Pennsylvania、アメリカ、18015
- Saint Luke's Neurosurgical Associates
-
Sewickley、Pennsylvania、アメリカ、15134
- Pain Diagnostics and Interventional Care
-
Trevose、Pennsylvania、アメリカ、19053
- Delaware Valley Pain and Spine Institute
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29406
- Lowcountry Orthopaedics/Coastal Carolina Research Center
-
Spartanburg、South Carolina、アメリカ、29303
- Carolina Center for Advanced Management of Pain
-
-
Texas
-
Tyler、Texas、アメリカ、75701
- Precision Spine Care
-
-
Virginia
-
Roanoke、Virginia、アメリカ、24014
- Carilion Clinic Roanoke Memorial Hospital
-
-
Washington
-
Spokane、Washington、アメリカ、99201
- Northwest Pain Care
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Candidate per labeling for an SCS system as an aid in the management of chronic, intractable low back and leg pain
- Presence of low back and leg pain
- Moderate to crippled disability due to pain
- Stable pain medications for back and leg pain for at least 28 days prior to enrollment
- Willing and able to not increase pain medications through the 3-Month visit
Exclusion Criteria:
- Previously trialed or implanted with stimulator or intrathecal drug delivery system
- Current diagnosis of moderate to severe central lumbar spinal stenosis
- Major psychiatric comorbidity or other progressive diseases
- Serious drug-related behavioral issues
- Pregnant or planning on becoming pregnant
- Unable to achieve supine position
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Treated
Enrolled subjects who are implanted with a spinal cord stimulation system that is activated.
|
Implanted neurostimulation system (neurostimulator and leads) with high dose stimulation parameters.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Overall Pain Intensity on the Visual Analog Scale (0-100)
時間枠:Baseline to 3 months
|
Demonstrate a significant improvement in overall pain intensity as measured by the Visual Analog Scale (VAS). The VAS ranges from 0 (no pain) to 100 (worst pain imaginable). The change in overall pain intensity is calculated as the Baseline VAS minus the 3-month VAS, where a positive value indicates an improvement (ie, reduction) in pain from Baseline to 3 months. Higher values represent a larger reduction (ie, greater improvement) in pain. The change in overall pain intensity as measured by the VAS can range from -100 (worsening in pain from 0 at baseline to 100 at 3 months) to 100 (improvement in pain from 100 at baseline to 0 at 3 months). It should be noted that while the change in VAS can range from -100 to 100, no subjects had a VAS of 0 at baseline, as the presence of pain was required for eligibility for inclusion in the study. |
Baseline to 3 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Pain Efficacy Responder Rate
時間枠:Baseline to 3 months
|
Characterize the overall pain efficacy responder rate, where the responder rate is the percentage of subjects who experience at least a 50% improvement in overall pain, as measured by the Visual Analog Scale (VAS). The VAS ranges from 0 (no pain) to 100 (worst pain imaginable). The percent improvement for each subject was calculated as [100*(Baseline VAS - 3-month VAS)/Baseline VAS], where a positive number represents an improvement, and the larger the number the greater the percent improvement. If the percent improvement from baseline to 3 months was at least 50%, the subject was considered a responder. The percentage of subjects who experience at least a 50% improvement in overall pain can range from 0% (no responders) to 100% (all responders). |
Baseline to 3 months
|
|
Low Back Pain Efficacy Responder Rate
時間枠:Baseline to 3 months
|
Characterize the low back pain efficacy responder rate, where the responder rate is the percentage of subjects who experience at least a 50% improvement in low back pain, as measured by the Visual Analog Scale (VAS). The VAS ranges from 0 (no pain) to 100 (worst pain imaginable). The percent improvement for each subject was calculated as [100*(Baseline VAS - 3-month VAS)/Baseline VAS], where a positive number represents an improvement, and the larger the number the greater the percent improvement. If the percent improvement from baseline to 3 months was at least 50%, the subject was considered a responder. The percentage of subjects who experience at least a 50% improvement in low back pain can range from 0% (no responders) to 100% (all responders). |
Baseline to 3 months
|
|
Leg Pain Efficacy Responder Rate
時間枠:Baseline to 3 months
|
Characterize the leg pain efficacy responder rate, where the responder rate is the percentage of subjects who experience at least a 50% improvement in leg pain, as measured by the Visual Analog Scale (VAS). The VAS ranges from 0 (no pain) to 100 (worst pain imaginable). The percent improvement for each subject was calculated as [100*(Baseline VAS - 3-month VAS)/Baseline VAS], where a positive number represents an improvement, and the larger the number the greater the percent improvement. If the percent improvement from baseline to 3 months was at least 50%, the subject was considered a responder. The percentage of subjects who experience at least a 50% improvement in leg pain can range from 0% (no responders) to 100% (all responders). |
Baseline to 3 months
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Vectors Post Market Clinical Research Study Team、Medtronic Restorative Therapies, Pain Therapy
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
慢性の痛みの臨床試験
-
Bingol UniversityAtaturk Universityまだ募集していません術前不安 | 恐れ | PAİN
-
Dexa Medica Group完了
Spinal Cord Stimulation Systemの臨床試験
-
Saluda Medical Americas, Inc.完了
-
Saluda Medical Pty Ltd積極的、募集していない慢性の痛みイギリス, オランダ, ドイツ, ベルギー